吲哚美辛靶向环氧合酶延缓急性淋巴细胞白血病异种移植模型进展
本研究利用人原代急性淋巴细胞白血病(ALL)细胞非肥胖糖尿病-scid IL2rγnull小鼠异种移植模型,发现饮水中给予环氧合酶(COX)抑制剂吲哚美辛可延缓ALL体内进展。进展通过无创活体成像及实验终点脾或骨髓中CD19+CD10+白血病原始细胞分析监测。吲哚美辛治疗提高了白血病细胞p53水平,提示COX抑制可能通过减弱骨髓基质对白血病细胞保护性旁分泌PGE2信号来减少ALL进展。
要点
- 吲哚美辛饮水给药可延缓人原代ALL细胞异种移植小鼠的疾病进展。
- 疗效与白血病细胞p53水平升高相关,提示COX抑制减弱基质PGE2保护信号。
- 骨髓基质来源PGE2可能是改善儿童ALL治疗的潜在靶点。
核心结论
- COX抑制剂吲哚美辛通过饮水给药可延缓人原代ALL细胞在NOD-scid IL2rγnull小鼠中的体内进展。
- 吲哚美辛治疗增加白血病细胞p53水平,提示COX抑制可能通过减弱骨髓基质旁分泌PGE2保护信号延缓ALL进展。
研究设计与样本
- 研究采用人原代ALL细胞非肥胖糖尿病-scid IL2rγnull小鼠异种移植模型。
- 吲哚美辛通过饮水给药,进展通过无创活体成像及实验终点脾或骨髓CD19+CD10+白血病原始细胞分析监测。
主要发现
- 吲哚美辛饮水给药延迟了ALL在小鼠体内的进展。
- 吲哚美辛治疗提高了白血病细胞中p53的水平。
- 骨髓基质细胞释放的PGE2可能通过旁分泌信号保护白血病细胞,COX抑制可能减弱该信号。
临床怎么用
- 本研究为临床前异种移植模型结果,尚不能直接指导临床用药。
- 提示评估COX抑制剂联合策略时需关注骨髓微环境PGE2信号及p53状态。
局限性
- 研究仅基于NOD-scid IL2rγnull小鼠异种移植模型,尚未在人体验证。
- 原文未报告吲哚美辛剂量、给药时长及具体统计数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute lymphoblastic leukemia (ALL) develops in the bone marrow in the vicinity of stromal cells known to promote tumor development and treatment resistance. We previously showed that the cyclooxygenase (COX) inhibitor indomethacin prevents the ability of stromal cells to diminish p53-mediated killing of cocultured ALL cells in vitro, possibly by blocking the production of prostaglandin E2 (PGE2). Here, we propose that PGE2 released by bone marrow stromal cells might be a target for improved treatment of pediatric ALL. We used a xenograft model of human primary ALL cells in nonobese diabetic-scid IL2rγnull mice to show that indomethacin delivered in the drinking water delayed the progression of ALL in vivo. The progression was monitored by noninvasive in vivo imaging of the engrafted leukemic cells, as well as by analyses of CD19+CD10+ leukemic blasts present in spleen or bone marrow at the termination of the experiments. The indomethacin treatment increased the level of p53 in the leukemic cells, implying that COX inhibition might reduce progression of ALL by attenuating protective paracrine PGE2 signaling from bone marrow stroma to leukemic cells.
引用
- Richartz N, Duthil E, Ford A, et al. Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model. Blood Adv. 2019. PMID: 31698450. doi:10.1182/bloodadvances.2019000473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。